A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)

被引：2
|
作者：
Socinski, M. [1 ]
Gil, M. [2 ]
Shahidi, J. [3 ]
Chao, G. Y. [4 ]
Villaruz, L. [1 ]
机构：
[1] Univ Pittsburgh, Med Oncol, UPMC Canc Pavil, Pittsburgh, PA USA
[2] Eli Lilly Polska, Oncol, Warsaw, Poland
[3] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Biostat, Indianapolis, IN 46285 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.98
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1298TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer
    Zhefeng Liu
    Zhimin Wei
    Yi Hu
    Feng Gao
    Lu Hao
    Ping Fang
    Shengjie Sun
    Jinyu Li
    Shunchang Jiao
    Medical Oncology, 2015, 32
  • [32] Interim Results From the Phase I Study of Nivolumab plus nab-Paclitaxel plus Carboplatin in Non-Small Cell Lung Cancer (NSCLC)
    Goldman, Jonathan W.
    George, Ben
    Gutierrez, Martin
    Ko, Amy
    O'Dwyer, Peter
    Otterson, Gregory
    Soliman, Hatem
    Trunova, Nataliya
    Waterhouse, David
    Kelly, Karen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1309 - S1309
  • [33] BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab plus Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer
    Hainsworth, John D.
    Fang, Liang
    Huang, Jane E.
    Karlin, David
    Russell, Kenneth
    Faoro, Leonardo
    Azzoli, Christopher
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (01) : 109 - 114
  • [34] Perioperative serplulimab and chemotherapy in patients with resectable squamous non-small cell lung cancer: An open-label, single-arm, phase II trial
    Chen, H.
    Hu, H.
    Fu, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S787 - S787
  • [35] Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC).
    Hawkins, M. J.
    Georgy, M.
    Makhson, A.
    Cheporov, S.
    Sergey, O.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 397S - 397S
  • [36] Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naive, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis
    Chen, Yingkai
    Kang, Shizhou
    Yan, Ming
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (03):
  • [37] nab-Paclitaxel plus Carboplatin in Advanced Non-Small Cell Lung Cancer: Outcomes in Elderly Patients With Squamous Histology
    Gridelle, Cesare
    Chen, Tianlei
    Ko, Amy
    Ong, Teng Jin
    O'Brien, Mary
    Socinski, Mark
    Postmus, Pieter
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S213 - S213
  • [38] A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC)
    Johnson, M.
    Wacheck, V.
    Hussein, M.
    McCleod, M.
    Daniel, D.
    Waterhouse, D.
    Gil, M.
    Strickland, D.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hirsh, V.
    Page, R. D.
    Ko, A.
    Renshler, M.
    Socinski, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S43 - S43
  • [40] nab-Paclitaxel plus Carboplatin in Advanced Non-Small Cell Lung Cancer NSCLC: Dose Modification Analysis
    Postmus, Pieter E.
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Li, Li
    Ong, Teng Jin
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S658 - S658
12345